Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1099/ijsem.0.004391 | DOI Listing |
Nephrol Dial Transplant
November 2024
Department of Medicine and Nephrology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Background And Hypothesis: Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is approved for treatment of anemia in dialysis patients with CKD in some parts of the world. This subgroup analysis examined the efficacy and safety of daprodustat versus darbepoetin alfa in patients with anemia of CKD undergoing peritoneal dialysis (PD).
Methods: ASCEND-D (NCT02879305) was an open-label, Phase 3 trial; patients with CKD were randomized to daprodustat daily and epoetin alfa (HD patients) or darbepoetin alfa (PD patients).
Kidney Med
February 2025
Division of Renal Diseases and Hypertension, Department of Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX.
ACS EST Air
January 2025
Department of Earth Sciences, University of Southern California, Los Angeles, California 90089, United States.
Computational models of atmospheric composition are not always physically consistent. For example, not all models respect fundamental conservation laws such as conservation of atoms in an interconnected chemical system. In well performing models, these unphysical deviations are often ignored because they are frequently minor, and thus only need a small nudge to perfectly conserve mass.
View Article and Find Full Text PDFAnn Transl Med
December 2024
Medical Direction, Rovereto Hospital, Provincial Agency for Social and Sanitary Services (APSS), Trento, Italy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!